US OptionsDetailed Quotes
ZNTL250117C7500
- 0.65
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.65Open0.65Pre Close0 Volume256 Open Interest7.50Strike Price0.00Turnover0.00%IV263.84%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.65Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.45Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Zentalis Pharmaceuticals Stock Discussion
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
109
35
16
$Zentalis Pharmaceuticals (ZNTL.US)$ Zentalis Gets FDA Fast-Track Designation for Azenosertib
WSJ· 07:211min
Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 protein.
The San Diego clinical-stage biopharmaceutical company on Thursday said the designation covers azenosertib for the treatment of patients with platinum-resistant epith...
WSJ· 07:211min
Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 protein.
The San Diego clinical-stage biopharmaceutical company on Thursday said the designation covers azenosertib for the treatment of patients with platinum-resistant epith...
$Zentalis Pharmaceuticals (ZNTL.US)$
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
Thursday, 9th January at 7:00 am
Azenosertib Fast Track Designation granted for Cyclin E1 positive patients by U.S. Food and Drug Administration (FDA)
Manuscript focused on role of Cyclin E1/CDK2 activation predicting sensitivity to azenosertib published in npj Precision Oncology
Corporate event to ...
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
Thursday, 9th January at 7:00 am
Azenosertib Fast Track Designation granted for Cyclin E1 positive patients by U.S. Food and Drug Administration (FDA)
Manuscript focused on role of Cyclin E1/CDK2 activation predicting sensitivity to azenosertib published in npj Precision Oncology
Corporate event to ...
2
$Zentalis Pharmaceuticals (ZNTL.US)$ wall is down lets go fly
2
$Zentalis Pharmaceuticals (ZNTL.US)$ we have to bid the $4.25 wall to let it fly.
2
$Zentalis Pharmaceuticals (ZNTL.US)$ 4.30 by 10am let it go
1
$Zentalis Pharmaceuticals (ZNTL.US)$ 4 buy 9:45
1
1
No comment yet
151158967 : Thank you, @Jaguar8 . Your hard work is appreciated!
103687630 : I think, what do you think of ONDS? There was good news on Wednesday but it went down. Do you think there is a chance for a rebound?
Jaguar8 OP 103687630 : I didn’t choose it because it didn’t specify how much is the contract.
103687630 Jaguar8 OP : Okay, thank you for your reply
70761249 : Can VERI make a breakthrough in the short term? The recent wildfires in Southern California are really heartbreaking, causing significant disappointment in the credibility of the media and government.
View more comments...